$ALHC

KAO JOHN E sold $2.2M of ALHC (indirect holdings)

KAO JOHN E (Chief Executive Officer) sold 172,600 indirectly-held shares of Alignment Healthcare, Inc. (ALHC) at $12.96 ($2.24M total) on 2026-09-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · KAO JOHN E
Published Sep 12, 2026, 12:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 12, 2026, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALHC
Bearish
high confidence
Mentioned
$ALHC
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALHCBearishMed
01

Why it matters

The transaction reduces insider ownership by roughly 22%, which may be interpreted as a negative signal by investors and could trigger short‑term price weakness.

02

Market read

Insider sell of this magnitude by the CEO is a material event for ALHC, likely influencing short‑term trading sentiment.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed may be driving the sell.

Relevance 5/10Novelty 8/10Timing: after market on 2026-09-10

Background

Form 4 filings provide the first public disclosure of insider transactions; this sale is the first report of the CEO's recent share reduction.

Company-level read

Ticker impact

$ALHCBearishHigh confidence
Context

CEO John E. Kao sold 172,600 shares for $2.24M via a 10b5‑1 plan, reducing his stake to 618,166 shares.

Expected impact

Potential short‑term downside pressure; traders may consider short positions or reduce long exposure.

Evidence & confidence

The sale size exceeds $2M and is executed under a pre‑arranged plan, indicating a material insider transaction that markets typically view as bearish.

Market effects

May weigh on other healthcare small‑caps as insider sells can raise sector‑wide risk concerns.

Limited to U.S. markets; no broader regional effect.

Low; impact confined to Alignment Healthcare and its immediate peers.

Counterpoint

The sale could be purely liquidity‑driven under the 10b5‑1 plan, not a confidence signal.

Key entities

  • Alignment Healthcare, Inc.

    U.S. listed healthcare company (ticker ALHC).

  • John E. Kao

    Chief Executive Officer of Alignment Healthcare.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALHCMed

Alignment Shares Tumble on Rising Medical Costs

Alignment Healthcare (ALHC) shares fell 16% after executives cited rising medical costs and claims system issues. CEO John Kao noted the company is addressing these challenges. Despite a 47% drop in the past year, the company maintained its revenue guidance. TD Cowen reiterated a Buy rating with a $21 price target. Alignment is expanding its network with Hoag Memorial Hospital.

$ALHCMed

ALHC Stock Slides As Legal And Cost Pressures Mount

Alignment Healthcare Inc. (ALHC) shares fell 3.61% on September 18, 2026, due to investor concerns over Medicare Advantage reimbursement and regulatory pressures. The stock has dropped significantly from $13–$14 to around $8.35, with technical damage and high volatility. Management cited Q3 medical cost headwinds and additional investments, while a whistleblower alleged expense misclassification, leading to legal probes. Insider selling and weak sentiment have further pressured the stock.

$ALHCMed

Alignment Healthcare extends retreat, falls an additional 16% (ALHC:NASDAQ)

Alignment Healthcare (ALHC) shares fell 16% on Wednesday, extending a 20% drop from the prior session. Management cited planned investments and medical-cost pressures at the Baird 2026 Global Healthcare Conference. The stock reached a 52-week low at $8.71, trading 45-54% below its 50/200-day averages. An analyst upgraded ALHC to Buy, noting operational progress but warning of potential volatility.

$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

$ALHCMed

ALHC Stock Tumbles After ‘Don’t Poke the Bear’ Silence On Star Ratings — CLOV Falls With It

Alignment Healthcare (ALHC) shares dropped 22% after executives declined to discuss next year's quality bonus and noted higher-than-expected hospital bills. CEO John Kao cited CMS sensitivity about commenting on Plan Preview 2. Clover Health (CLOV) also fell 9%. ALHC's CFO mentioned institutional cost headwinds but expects them to ease by 2027. Guidance remained unchanged.

$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.